Clinical Trial Update: Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating zoledronic acid and markers of bone resorption to predict bone metastases and cancer treatment-induced bone loss in men with prostate c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cancer Prostate | Phase 3 | Status: COMPLETED